Nanostring Technologies Inc   (NSTG)
Other Ticker:  
Price: $0.1053 $-0.06 -37.433%
Day's High: $0.14 Week Perf: 97.93 %
Day's Low: $ 0.10 30 Day Perf: -73.68 %
Volume (M): 23,061 52 Wk High: $ 11.02
Volume (M$): $ 2,428 52 Wk Avg: $3.81
Open: $0.13 52 Wk Low: $0.05

 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 48
 Employees 721
 Revenues (TTM) (Millions $) 162
 Net Income (TTM) (Millions $) -166
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 21

Nanostring Technologies Inc
NanoString Technologies Inc.
is a leading diagnostic and biotechnology company that specializes in the development and commercialization of molecular diagnostic tests and genomic research tools.
The company uses a proprietary technology called the nCountere Analysis System that offers high levels of precision, sensitivity and reproducibility in detecting and quantifying nucleic acids.
The nCountere Analysis System provides a unique solution to understanding the biology of diseases at a molecular level.
It allows researchers to simultaneously measure the expression levels of hundreds of genes, coding and non-coding RNA species, and copy number variations within a single sample.
This powerful technology doesnet require any amplification or labeling, making it faster than other methods, while still providing high-resolution data.
NanoString Technologiese product portfolio includes several diagnostic assays in the areas of clinical oncology, immunology, neurology, and infectious disease.
The companyes flagship product is the Prosignae Breast Cancer Prognostic Gene Signature Assay, which is FDA-approved for use in postmenopausal women with early-stage breast cancer.
The test helps clinicians to determine which patients may not require chemotherapy after surgery, thereby minimizing the risk of unnecessary treatment.
In addition to its diagnostic assays, NanoString Technologies also provides a range of research tools including the nCountere Analysis System, gene expression panels and assays, protein array products, and digital spatial profiling platform for spatially resolved tissue analysis.
NanoString Technologies have exclusive collaborations with major pharmaceutical companies such as Merck, Pfizer, and Biogen, who use the companyes technology to develop new therapeutics and clinical biomarkers.
NanoString Technologies went public in 2013, and currently has its headquarters in Seattle, Washington.
The company has several offices worldwide, including in Europe and Asia-Pacific.
It continues to lead innovation in the genomics industry with its state-of-the-art technology and diagnostic solutions.

   Company Address: 530 Fairview Avenue North Seattle 98109 WA
   Company Phone Number: 378-6266   Stock Exchange / Ticker: NASDAQ NSTG


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Financing Agreement

NanoString Technologies Secures Financing to Support Restructuring Process

Published Fri, Feb 9 2024 11:30 AM UTC

NanoString Technologies, Inc., a prominent provider of life science tools for research, has announced the completion of a financing deal to bolster its restructuring efforts. The company has entered into a credit agreement with its existing lenders, paving the way for $47.5 million in new term loans. This funding, approved by the U.S. Bankruptcy court, will support Nano...

Product Service News

Revolutionary Breakthrough: NanoString Launches CosMx 6,000 Plex RNA Assay and Pioneers Whole Transcriptome Imaging Capability

Published Thu, Feb 1 2024 11:00 AM UTC

NanoString Technologies, Inc., a renowned leader in life science tools for discovery and translational research, has recently unveiled the CosMx Human 6K Discovery Panel. This revolutionary single-cell spatial panel is a breakthrough product that offers research scientists the ability to analyze over 6,000 RNA targets, thereby covering nearly every human biological pathway. ...

Product Service News

Unraveling Cellular Mysteries: NanoString's CosMx SMI Generates Revolutionary Transcriptomics Dataset at Single-Cell Resolution

Published Sun, Jan 7 2024 8:00 PM UTC

Combining the Power of NanoStrings CosMx SMI: Achieving Whole Transcriptome Imaging at Single-Cell ResolutionSeamlessly fusing cutting-edge technology with the realm of life sciences, NanoString Technologies Inc. (NASDAQ: NSTG) has unveiled a groundbreaking achievement in research tools ?? the first public dataset of the whole transcriptome obtained at true single-cell resol...

Nanostring Technologies Inc

Nanostring Technologies Inc Achieves Impressive Revenue Growth, Driving Reduction in Losses during Q3 20232.

Interpreting the Financial Results of Nanostring Technologies Inc
As a biotechnology and pharmaceuticals company, Nanostring Technologies Inc has surprised many with its respectable revenue advance in the latest financial report ending on September 30, 2023. The company experienced a significant growth of 62.787% in revenue, reaching $48.09 million. This surge in revenue has helped Nanostring Technologies Inc to reduce its losses to -$0.78 per share, compared to -$0.79 per share in the same reporting season a year ago.
Interestingly, Nanostring Technologies Inc's positive results contrast with the overall performance of the biotechnology and pharmaceuticals sector, which saw an unfortunate decline of -11.52% in revenue. This makes Nanostring Technologies Inc stand out as a shining star among its peers. In the previous quarter, the company also witnessed an 8.905% increase in revenue from $44.16 million. Additionally, its earnings per share (EPS) also improved from -$0.92 to -$0.78 per share.

Nanostring Technologies Inc

Despite Revenue Surge, Nanostring Technologies Inc Remains Unprofitable in Q2 2023; Records Greater Loss Per Share

The financial results for Nanostring Technologies Inc in the fiscal three months ending June 30, 2023, have shown both positive and negative aspects. Firstly, the company experienced a loss per share of $-0.92, which is an increase compared to the previous financial reporting period. This may be regarded as disappointing news for shareholders.
However, despite the increase in loss per share, Nanostring Technologies Inc achieved a significant surge in revenue. The top-line advanced by 37.053% to $44.16 million compared to the similar period a year ago. This growth in revenue outpaced most of its peers in the Biotechnology & Pharmaceuticals sector, where the average top-line advance was only 1.21% in the same quarter.


Nanostring Technologies Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com